Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Richtech Robotics Inc. for alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by April 3, 2026 [1] Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in Richtech to contact them directly to discuss their legal options [1] - The complaint alleges that Richtech and its executives made false and misleading statements regarding a non-existent collaborative relationship with Microsoft [1] - The stock price of Richtech fell by $1.06, or 20.87%, closing at $4.02 on January 29, 2026, following a critical report questioning the company's Microsoft collaboration [1] Group 2: Class Action Details - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of class members [1] - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [1] - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Richtech's conduct [1]

Core Viewpoint - Vistagen Therapeutics, Inc. is facing a federal securities class action due to allegations of misleading statements regarding the efficacy of its drug fasedienol, leading to significant financial losses for investors [1] Summary by Relevant Sections Company Overview - Vistagen Therapeutics, Inc. (NASDAQ: VTGN) is under investigation by Faruqi & Faruqi, LLP for potential violations of federal securities laws [1] Legal Action - A class action lawsuit has been filed against Vistagen, with a deadline for investors to seek lead plaintiff status set for March 16, 2026 [1] - The complaint alleges that Vistagen made false assertions about the success of fasedienol based on prior clinical trial results, which misled investors [1] Financial Impact - On December 17, 2025, Vistagen announced that its PALISADE-3 clinical trial for fasedienol failed to meet its primary efficacy endpoint, resulting in an over 81% drop in stock price to $0.88 per share [1]

FBRT SHAREHOLDER ACTION ANNOUNCEMENT: Faruqi & Faruqi, LLP Reminds Franklin BSP Realty Trust (FBRT) Investors of Securities Class Action Deadline on April 27, 2026 [Accessibility Statement] Skip NavigationFaruqi & Faruqi, LLP Securities Litigation Partner [James (Josh) Wilson] Encourages Investors Who Suffered Losses In Franklin To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in [Franklin] between November 5, 2024 and February 11, 2026 and would like to discuss your l ...

NAVN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Navan (NAVN) Investors of Securities Class Action Deadline on April 24, 2026 [Accessibility Statement] Skip NavigationFaruqi & Faruqi, LLP Securities Litigation Partner [James (Josh) Wilson] Encourages Investors Who Suffered Losses In Navan To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in [Navan] pursuant to and/or traceable to the Company's Registration Statement and Prospectus (collectively, the "Offer ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against NuScale Power Corporation due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by April 20, 2026 [1] Company Overview - NuScale Power Corporation (NYSE: SMR) is facing a federal securities class action for allegedly making false or misleading statements regarding its operations and partnerships [1] - The complaint highlights that NuScale's partner, ENTRA1, had no significant experience in nuclear power generation, which raises concerns about the company's commercialization strategy [1] Financial Performance - In the third fiscal quarter of 2025, NuScale reported a dramatic increase in general and administrative expenses, which surged over 3,000% to $519 million from $17 million in the same period the previous year [1] - The company's net loss for the quarter escalated to $532 million, compared to a loss of $46 million in the prior year [1] Stock Performance - Following the financial disclosures on November 6, 2025, NuScale's Class A shares dropped over 12% within two days, from approximately $32 to about $28 [1] - The stock continued to decline, reaching a low of $17 per share by November 21, 2025, representing a decrease of more than 70% from its class period high of over $57 [1]

TCPC SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Beyond Meat (TCPC) Investors of Securities Class Action Deadline on March 24, 2026 [Accessibility Statement] Skip NavigationFaruqi & Faruqi, LLP Securities Litigation Partner [James (Josh) Wilson] Encourages Investors Who Suffered Losses In BlackRock TCP To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in [BlackRock TCP] between November 6, 2024 and January 23, 2026 and would like to discuss your legal righ ...

MREO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026 [Accessibility Statement] Skip NavigationFaruqi & Faruqi, LLP Securities Litigation Partner [James (Josh) Wilson] Encourages Investors Who Suffered Losses In Mereo BioPharma To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in [Mereo BioPharma] between June 5, 2023 and December 26, 2025 and would like to discuss your legal ...

ARDT SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ardent Health (ARDT) Investors of Securities Class Action Deadline on April 21, 2026 [Accessibility Statement] Skip NavigationFaruqi & Faruqi, LLP Securities Litigation Partner [James (Josh) Wilson] Encourages Investors Who Suffered Losses In Ardent To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in [Ardent] between July 18, 2024 and November 12, 2025 and would like to discuss your legal rights, call Faruq ...

Core Viewpoint - Driven Brands Holdings Inc. is under investigation for potential claims due to significant financial reporting errors that led to a 30% drop in its stock price [1] Financial Reporting Issues - Driven Brands delayed its fourth-quarter release due to material errors in financial statements for fiscal years 2023 and 2024 [1] - The company disclosed that its previously issued financial statements should not be relied upon and require restatement [1] - Errors identified include lease recording issues affecting right of use assets and liabilities, cash account discrepancies leading to overstatements of cash and revenue, and overstated company-operated store expenses [1] Internal Control Weaknesses - Driven Brands identified material weaknesses in internal control over financial reporting [1] - The Report of its Independent Registered Public Accounting Firm on the financial statements and internal control should not be relied upon [1]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Snowflake To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Snowflake between June 27, 2023 and February 28, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Far ...